Fig. 3.
Sensitivity analysis showing the incremental cost-effectiveness ratios (ICERs) under the assumptions of number of malignant hyperthermia (MH) episodes per year ranging from 0 to 94 given MH case fatality with dantrolene being 0, 10, and 20%, MH case fatality without dantrolene being 30, 50, and 80%, number of vials of dantrolene being 24, 36, and 48, cost of dantrolene per vial being $101.25, and number of ambulatory surgery centers being 5,316.